Decision modelling using time on treatment data: evaluating the survival benefit of nilotinib versus imatinib in patients with chronic phase Ph+ CML

Mildred, Matthew, Ward, Sue, Squires, Hazel and Gray, Elizabeth (2012) Decision modelling using time on treatment data: evaluating the survival benefit of nilotinib versus imatinib in patients with chronic phase Ph+ CML. In: 9th Annual Health Technology Assessment Society (HTAi) Meeting, 25-27 June 2012, Bilbao, Spain.

Abstract

Metadata

Authors/Creators:
  • Mildred, Matthew
  • Ward, Sue
  • Squires, Hazel
  • Gray, Elizabeth
Keywords: Antineoplastic Agents; Clinical Trials; Cost-Benefit Analysis; Drug Costs; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Health Economics and Decision Science
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Funding Information:
FunderGrant number
Novartis Pharmaceuticals UK LtdUNSPECIFIED
Depositing User: Mr Matthew Mildred
Date Deposited: 18 May 2012 10:07
Last Modified: 04 Jun 2014 18:54
Status: Published
Refereed: Yes

Download

Filename: Mildred_2012_HTAi_poster.pdf

Share / Export